{"id":16618,"date":"2022-03-10T16:39:14","date_gmt":"2022-03-10T15:39:14","guid":{"rendered":"http:\/\/mabdesign.fr\/domain-therapeutics-et-explicyte-signent-un-accord-de-partenariat-en-immuno-oncologie\/"},"modified":"2022-03-10T16:39:14","modified_gmt":"2022-03-10T15:39:14","slug":"domain-therapeutics-et-explicyte-signent-un-accord-de-partenariat-en-immuno-oncologie","status":"publish","type":"post","link":"https:\/\/mabdesign.fr\/en\/domain-therapeutics-et-explicyte-signent-un-accord-de-partenariat-en-immuno-oncologie\/","title":{"rendered":"Domain Therapeutics et Explicyte signent un accord de partenariat en immuno-oncologie"},"content":{"rendered":"

Explicyte octroie \u00e0 Domain Therapeutics l\u2019exclusivit\u00e9 sur des donn\u00e9es relatives aux RCPG impliqu\u00e9s dans l\u2019immunor\u00e9sistance, pour le d\u00e9veloppement de th\u00e9rapies anticanc\u00e9reuses first-in-class<\/strong><\/p>\n

Strasbourg et Bordeaux, France, 10 mars 2022 \u2013 Domain Therapeutics<\/strong>, une soci\u00e9t\u00e9 biopharmaceutique sp\u00e9cialis\u00e9e dans la d\u00e9couverte et le d\u00e9veloppement de nouveaux m\u00e9dicaments ciblant les r\u00e9cepteurs coupl\u00e9s aux prot\u00e9ines G (RCPG) en immuno-oncologie (IO), et Explicyte<\/strong>, un expert dans le domaine de l\u2019IO et l\u2019identification de cibles innovantes \u00e0 travers des approches multi-param\u00e9triques, annoncent aujourd\u2019hui la signature d\u2019un accord de partenariat. Les deux soci\u00e9t\u00e9s vont combiner leur expertise pour identifier les cibles RCPG et les biomarqueurs associ\u00e9s, dans le but de d\u00e9couvrir et de d\u00e9velopper des programmes th\u00e9rapeutiques r\u00e9volutionnaires en IO.<\/p>\n

En savoir plus<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Explicyte octroie \u00e0 Domain Therapeutics l\u2019exclusivit\u00e9 sur des donn\u00e9es relatives aux RCPG impliqu\u00e9s dans l\u2019immunor\u00e9sistance, pour le d\u00e9veloppement de th\u00e9rapies anticanc\u00e9reuses first-in-class<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9,13],"tags":[],"class_list":["post-16618","post","type-post","status-publish","format-standard","hentry","category-actualites","category-nos-adherents"],"yoast_head":"\nDomain Therapeutics et Explicyte signent un accord de partenariat en immuno-oncologie - MabDesign<\/title>\n<meta name=\"description\" content=\"Explicyte octroie \u00e0 Domain Therapeutics l\u2019exclusivit\u00e9 sur des donn\u00e9es relatives aux RCPG impliqu\u00e9s dans l\u2019immunor\u00e9sistance, pour le d\u00e9veloppement de th\u00e9rapies anticanc\u00e9reuses first-in-class\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mabdesign.fr\/en\/domain-therapeutics-et-explicyte-signent-un-accord-de-partenariat-en-immuno-oncologie\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Domain Therapeutics et Explicyte signent un accord de partenariat en immuno-oncologie - MabDesign\" \/>\n<meta property=\"og:description\" content=\"Explicyte octroie \u00e0 Domain Therapeutics l\u2019exclusivit\u00e9 sur des donn\u00e9es relatives aux RCPG impliqu\u00e9s dans l\u2019immunor\u00e9sistance, pour le d\u00e9veloppement de th\u00e9rapies anticanc\u00e9reuses first-in-class\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mabdesign.fr\/en\/domain-therapeutics-et-explicyte-signent-un-accord-de-partenariat-en-immuno-oncologie\/\" \/>\n<meta property=\"og:site_name\" content=\"MabDesign\" \/>\n<meta property=\"article:published_time\" content=\"2022-03-10T15:39:14+00:00\" \/>\n<meta name=\"author\" content=\"alexis.mathias@kairios.fr\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:site\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"alexis.mathias@kairios.fr\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mabdesign.fr\/en\/domain-therapeutics-et-explicyte-signent-un-accord-de-partenariat-en-immuno-oncologie\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/domain-therapeutics-et-explicyte-signent-un-accord-de-partenariat-en-immuno-oncologie\/\"},\"author\":{\"name\":\"alexis.mathias@kairios.fr\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135\"},\"headline\":\"Domain Therapeutics et Explicyte signent un accord de partenariat en immuno-oncologie\",\"datePublished\":\"2022-03-10T15:39:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/domain-therapeutics-et-explicyte-signent-un-accord-de-partenariat-en-immuno-oncologie\/\"},\"wordCount\":151,\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"articleSection\":[\"Actualit\u00e9s\",\"Nos adh\u00e9rents\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mabdesign.fr\/en\/domain-therapeutics-et-explicyte-signent-un-accord-de-partenariat-en-immuno-oncologie\/\",\"url\":\"https:\/\/mabdesign.fr\/en\/domain-therapeutics-et-explicyte-signent-un-accord-de-partenariat-en-immuno-oncologie\/\",\"name\":\"Domain Therapeutics et Explicyte signent un accord de partenariat en immuno-oncologie - MabDesign\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\"},\"datePublished\":\"2022-03-10T15:39:14+00:00\",\"description\":\"Explicyte octroie \u00e0 Domain Therapeutics l\u2019exclusivit\u00e9 sur des donn\u00e9es relatives aux RCPG impliqu\u00e9s dans l\u2019immunor\u00e9sistance, pour le d\u00e9veloppement de th\u00e9rapies anticanc\u00e9reuses first-in-class\",\"breadcrumb\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/domain-therapeutics-et-explicyte-signent-un-accord-de-partenariat-en-immuno-oncologie\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mabdesign.fr\/en\/domain-therapeutics-et-explicyte-signent-un-accord-de-partenariat-en-immuno-oncologie\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mabdesign.fr\/en\/domain-therapeutics-et-explicyte-signent-un-accord-de-partenariat-en-immuno-oncologie\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/mabdesign.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Domain Therapeutics et Explicyte signent un accord de partenariat en immuno-oncologie\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"name\":\"Mabdesign\",\"description\":\"The Biotherapy Expert\",\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mabdesign.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\",\"name\":\"Mabdesign\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"width\":786,\"height\":233,\"caption\":\"Mabdesign\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/MabDesign_fr\",\"https:\/\/www.linkedin.com\/company\/mabdesign\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135\",\"name\":\"alexis.mathias@kairios.fr\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g\",\"caption\":\"alexis.mathias@kairios.fr\"},\"sameAs\":[\"http:\/\/mabdesign.fr\"],\"url\":\"https:\/\/mabdesign.fr\/en\/author\/amathiasigtcreative-fr\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Domain Therapeutics et Explicyte signent un accord de partenariat en immuno-oncologie - MabDesign","description":"Explicyte octroie \u00e0 Domain Therapeutics l\u2019exclusivit\u00e9 sur des donn\u00e9es relatives aux RCPG impliqu\u00e9s dans l\u2019immunor\u00e9sistance, pour le d\u00e9veloppement de th\u00e9rapies anticanc\u00e9reuses first-in-class","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mabdesign.fr\/en\/domain-therapeutics-et-explicyte-signent-un-accord-de-partenariat-en-immuno-oncologie\/","og_locale":"en_US","og_type":"article","og_title":"Domain Therapeutics et Explicyte signent un accord de partenariat en immuno-oncologie - MabDesign","og_description":"Explicyte octroie \u00e0 Domain Therapeutics l\u2019exclusivit\u00e9 sur des donn\u00e9es relatives aux RCPG impliqu\u00e9s dans l\u2019immunor\u00e9sistance, pour le d\u00e9veloppement de th\u00e9rapies anticanc\u00e9reuses first-in-class","og_url":"https:\/\/mabdesign.fr\/en\/domain-therapeutics-et-explicyte-signent-un-accord-de-partenariat-en-immuno-oncologie\/","og_site_name":"MabDesign","article_published_time":"2022-03-10T15:39:14+00:00","author":"alexis.mathias@kairios.fr","twitter_card":"summary_large_image","twitter_creator":"@MabDesign_fr","twitter_site":"@MabDesign_fr","twitter_misc":{"Written by":"alexis.mathias@kairios.fr","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mabdesign.fr\/en\/domain-therapeutics-et-explicyte-signent-un-accord-de-partenariat-en-immuno-oncologie\/#article","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/domain-therapeutics-et-explicyte-signent-un-accord-de-partenariat-en-immuno-oncologie\/"},"author":{"name":"alexis.mathias@kairios.fr","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135"},"headline":"Domain Therapeutics et Explicyte signent un accord de partenariat en immuno-oncologie","datePublished":"2022-03-10T15:39:14+00:00","mainEntityOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/domain-therapeutics-et-explicyte-signent-un-accord-de-partenariat-en-immuno-oncologie\/"},"wordCount":151,"publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"articleSection":["Actualit\u00e9s","Nos adh\u00e9rents"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mabdesign.fr\/en\/domain-therapeutics-et-explicyte-signent-un-accord-de-partenariat-en-immuno-oncologie\/","url":"https:\/\/mabdesign.fr\/en\/domain-therapeutics-et-explicyte-signent-un-accord-de-partenariat-en-immuno-oncologie\/","name":"Domain Therapeutics et Explicyte signent un accord de partenariat en immuno-oncologie - MabDesign","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/#website"},"datePublished":"2022-03-10T15:39:14+00:00","description":"Explicyte octroie \u00e0 Domain Therapeutics l\u2019exclusivit\u00e9 sur des donn\u00e9es relatives aux RCPG impliqu\u00e9s dans l\u2019immunor\u00e9sistance, pour le d\u00e9veloppement de th\u00e9rapies anticanc\u00e9reuses first-in-class","breadcrumb":{"@id":"https:\/\/mabdesign.fr\/en\/domain-therapeutics-et-explicyte-signent-un-accord-de-partenariat-en-immuno-oncologie\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mabdesign.fr\/en\/domain-therapeutics-et-explicyte-signent-un-accord-de-partenariat-en-immuno-oncologie\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/mabdesign.fr\/en\/domain-therapeutics-et-explicyte-signent-un-accord-de-partenariat-en-immuno-oncologie\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/mabdesign.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Domain Therapeutics et Explicyte signent un accord de partenariat en immuno-oncologie"}]},{"@type":"WebSite","@id":"https:\/\/mabdesign.fr\/en\/#website","url":"https:\/\/mabdesign.fr\/en\/","name":"Mabdesign","description":"The Biotherapy Expert","publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mabdesign.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mabdesign.fr\/en\/#organization","name":"Mabdesign","url":"https:\/\/mabdesign.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","width":786,"height":233,"caption":"Mabdesign"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/MabDesign_fr","https:\/\/www.linkedin.com\/company\/mabdesign\/"]},{"@type":"Person","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135","name":"alexis.mathias@kairios.fr","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g","caption":"alexis.mathias@kairios.fr"},"sameAs":["http:\/\/mabdesign.fr"],"url":"https:\/\/mabdesign.fr\/en\/author\/amathiasigtcreative-fr\/"}]}},"_links":{"self":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/16618","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/comments?post=16618"}],"version-history":[{"count":0,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/16618\/revisions"}],"wp:attachment":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media?parent=16618"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/categories?post=16618"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/tags?post=16618"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}